# Urethral cancer

Source: https://onco.cc/cancers/urethral/  
OnCo record `urethral` (Cancer). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Urethral cancer grows in the tube that carries urine out of the body, with fewer than one case per million people a year. With no randomised trials, it is treated by borrowing from bladder, anal or vulvar cancer depending on cell type and location; chemotherapy with radiotherapy before or instead of surgery lets more patients keep their organs.

## Summary

Primary urethral carcinoma is defined by where in the urethra it starts and by the lining it arises from: urothelial carcinoma in the prostatic and proximal urethra, squamous cell carcinoma in the distal (penile or anterior) urethra, and adenocarcinoma, often of Skene or Littre gland origin or arising in a diverticulum, particularly in women. Risk factors include chronic stricture and inflammation, prior radiotherapy, urethral diverticulum and HPV infection for squamous tumours. Presentation is with bleeding, obstruction or a palpable mass, and diagnosis is frequently delayed because symptoms mimic stricture or infection.

There are no randomised trials. Distal tumours are treated with organ-sparing surgery (partial urethrectomy or distal penectomy in men; distal urethrectomy in women) or with radiotherapy; proximal and locally advanced tumours have historically required radical cystoprostatectomy or anterior exenteration, but the modern approach favours neoadjuvant or definitive platinum-based chemotherapy with or without radiotherapy, extrapolated from bladder cancer (cisplatin-based combinations for urothelial histology) and anal or vulvar cancer (mitomycin or cisplatin with fluorouracil and radiotherapy for squamous histology). Multi-institutional series such as those from the international collaboration on primary urethral carcinoma show better survival with multimodal therapy than with surgery alone, and the EAU has published a dedicated guideline.

The practical frontier is applying advances from urothelial cancer (enfortumab vedotin with pembrolizumab, checkpoint inhibitors) and HPV-associated squamous cancers to this tiny population through basket trials and registries.

## Fields

- Kind: Cancer
- Last checked: 2026-09-10
- Also known as: Primary urethral carcinoma; Carcinoma of the urethra
- Tags: nci-coverage; rare; genitourinary
- Group: genitourinary
- Burden: One of the rarest genitourinary cancers, with fewer than one case per million per year in most registries; it is more common in men and in people over 60.
- Subtypes: Urothelial carcinoma (proximal and prostatic urethra); Squamous cell carcinoma (distal urethra; HPV-associated in some); Adenocarcinoma (including clear cell adenocarcinoma of the female urethra); Urethral melanoma (very rare)
- Biomarkers: Histology and site (drives treatment analogy); Clinical and MRI stage, nodal status; HPV / p16 in squamous tumours; PD-L1 and FGFR3 in urothelial histology (extrapolated from bladder cancer); Urine cytology and urethroscopy findings

## Sections of this record

The page is a hub with ten sections in reading order; large sections have their own page. The same plan as JSON: https://onco.cc/api/v1/cancers/urethral/sections.json

- Overview (on the hub): The TL;DR, the family this cancer belongs to, the organ, who gets it and what the state of the art is. https://onco.cc/cancers/urethral/#overview [4 subtypes, 3 state-of-the-art points]
- What it is (on the hub): Anatomy, the subtypes and how they differ, how it is staged, and where advanced disease spreads. https://onco.cc/cancers/urethral/#what-it-is [8 subtypes]
- Finding it (on the hub): How it shows itself, how it is confirmed, what screening exists, and the biomarkers clinicians test for. https://onco.cc/cancers/urethral/#finding-it [5 biomarkers]
- Treating it (on the hub): The standard of care by setting, the medicines, surgery and radiotherapy named in it, and the regimens behind them. https://onco.cc/cancers/urethral/#treating-it [3 settings, 2 decisions with options]
- Evidence (on the hub): Trials recruiting now, the landmark trials, the key papers and what they mean, the latest literature, and the milestones year by year. https://onco.cc/cancers/urethral/#evidence [3 milestones]
- The science (on the hub): The molecular landscape: the targets and how often each appears, the pathways, the mechanics stages and the preclinical models. https://onco.cc/cancers/urethral/#science [2 targets, 1 pathway]
- Where you are (own page): Cases by country, the UK and NHS pathway and other country lenses, and the expert centres with trials on record. https://onco.cc/cancers/urethral/where-you-are/
- Living with it (on the hub): The decisions you may face, the aids that walk through them, the warnings on record, the first sixty days and the questions to ask. https://onco.cc/cancers/urethral/#living-with-it [14 questions, 6 red cards]
- What is coming (own page): Everything in development, the open problems and what is being done about them, the roadmaps, and what changed on this record. https://onco.cc/cancers/urethral/coming/ [6 medicines, 3 open problems]
- Data (own page): Every connected record, the notes, the JSON, Markdown and RDF twins, and where the record came from and when it was checked. https://onco.cc/cancers/urethral/data/ [26 connected records]

## Standard of care

- Distal, localised: Organ-sparing surgery (distal urethrectomy, partial penectomy) or radiotherapy including brachytherapy. ([Brachytherapy](https://onco.cc/technologies/brachytherapy/))
- Proximal or locally advanced: Neoadjuvant platinum-based chemotherapy (or chemoradiation for squamous histology) followed by surgery; definitive chemoradiation as organ-preserving alternative. ([Cisplatin](https://onco.cc/drugs/cisplatin/), [Gemcitabine + cisplatin](https://onco.cc/drugs/gemcitabine-cisplatin/), [Fluorouracil (5-FU)](https://onco.cc/drugs/fluorouracil/), [Mitomycin C](https://onco.cc/drugs/mitomycin/), [IMRT / IGRT (modern external beam)](https://onco.cc/technologies/imrt-igrt/))
- Metastatic: Treat by histology: urothelial-type regimens (enfortumab vedotin plus pembrolizumab, gemcitabine-cisplatin) or squamous regimens; clinical trials. ([Enfortumab vedotin](https://onco.cc/drugs/enfortumab-vedotin/), [Pembrolizumab](https://onco.cc/drugs/pembrolizumab/), [Gemcitabine + cisplatin](https://onco.cc/drugs/gemcitabine-cisplatin/))

## State of the art

- Multimodal therapy (chemotherapy with radiotherapy or surgery) has largely replaced radical surgery alone, based on international retrospective collaborations.
- Treatment is chosen by histology, borrowing the best evidence from bladder cancer for urothelial tumours and from anal and vulvar cancer for squamous tumours.
- The EAU maintains the only dedicated guideline; registries and basket trials are the path to better evidence.

## Open problems

- No prospective trials; international registries and inclusion in urothelial and HPV-squamous basket trials are the response.
- Late diagnosis mimicking benign stricture; urethroscopy for unexplained stricture or bleeding is the practical fix.
- Balancing organ preservation with cure in proximal tumours; chemoradiation series are growing.

## Sources

- Wikipedia: https://en.wikipedia.org/wiki/Urethral_cancer
- NCI PDQ: urethral cancer: https://www.cancer.gov/types/urethral
- EAU Guidelines: Primary Urethral Carcinoma: https://uroweb.org/guidelines/primary-urethral-carcinoma

## Connected records

- cancers: [Adenocarcinoma of the urethra (including clear cell adenocarcinoma)](https://onco.cc/cancers/urethral-adenocarcinoma/), [Anal cancer (squamous cell carcinoma)](https://onco.cc/cancers/anal/), [Bladder & urothelial cancer](https://onco.cc/cancers/urothelial/), [Melanoma of the urethra](https://onco.cc/cancers/urethral-melanoma/), [Penile cancer](https://onco.cc/cancers/penile/), [Squamous cell carcinoma of the urethra](https://onco.cc/cancers/urethral-squamous-cell-carcinoma/), [Urothelial carcinoma of the urethra](https://onco.cc/cancers/urethral-urothelial-carcinoma/), [Vulvar cancer](https://onco.cc/cancers/vulvar/)
- technologies: [Antibody-drug conjugate (ADC)](https://onco.cc/technologies/adc/), [Brachytherapy](https://onco.cc/technologies/brachytherapy/), [Cytotoxic chemotherapy](https://onco.cc/technologies/cytotoxic-chemotherapy/), [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/), [IMRT / IGRT (modern external beam)](https://onco.cc/technologies/imrt-igrt/)
- targets: [Nectin-4](https://onco.cc/targets/nectin4/), [PD-1](https://onco.cc/targets/pd1/)
- terms: [Chemoradiation (chemoradiotherapy, CRT)](https://onco.cc/terms/chemoradiation/), [FGFR3 alterations (bladder cancer)](https://onco.cc/terms/fgfr3/), [HPV-positive (p16) head and neck cancer](https://onco.cc/terms/hpv-p16/)
- drugs: [Cisplatin](https://onco.cc/drugs/cisplatin/), [Enfortumab vedotin](https://onco.cc/drugs/enfortumab-vedotin/), [Fluorouracil (5-FU)](https://onco.cc/drugs/fluorouracil/), [Gemcitabine + cisplatin](https://onco.cc/drugs/gemcitabine-cisplatin/), [Mitomycin C](https://onco.cc/drugs/mitomycin/), [Pembrolizumab](https://onco.cc/drugs/pembrolizumab/)
- pathways: [Oncogenic viruses](https://onco.cc/pathways/oncogenic-viruses/)
- bottlenecks: [Rare and paediatric cancers without markets](https://onco.cc/bottlenecks/b-rare-cancers/)

---
JSON: https://onco.cc/api/v1/entities/urethral.json